Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of ($1.12), $0.20 worse than the analyst estimate of ($0.92). Revenue for the quarter came in at $138.4 million versus the consensus estimate of $137.03 million.

""We remain focused on building awareness of tardive dyskinesia and are encouraged by the continued adoption of INGREZZA among healthcare providers and the patient community. Importantly, a record number of new patients started treatment with INGREZZA during the first quarter," said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. "Within our product pipeline, we remain on track for the NDA submission of opicapone for Parkinson\'s disease, plan to discuss the registration program for congenital adrenal hyperplasia with the FDA, and look forward to making progress on the Parkinson\'s disease and Friedreich\'s ataxia gene therapy programs in collaboration with Voyager Therapeutics. We have laid the foundation to make meaningful strides throughout 2019 and work towards our goal of having three FDA-approved treatments in four indications by 2020."

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.